Eli Lilly | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
AbbVie USD 3.86B 306M 2024-12
Abbott USD 2.91B 21M 2024-12
ALKERMES USD 146.99M 3.39M 2024-12
Amgen USD 1.88B 253M 2024-12
AstraZeneca USD 5.55B 307M 2024-12
Baxter International USD 615M 16M 2024-12
Biogen USD 677.3M 99.6M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Drreddys Laboratories INR 21.59B 436M 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Gilead Sciences USD 1.86B 451M 2024-12
GlaxoSmithKline GBP 2.66B 1.14B 2024-12
Glaxosmithkline GBP 2.7B 632M 2024-12
Indivior 133M 11M 2024-09
J&J USD 6.45B 975M 2024-12
Medtronic USD 2.72B 34M 2025-01
Merck USD 2.85B 148M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Novartis USD 3.5B 368M 2024-12
Novo Nordisk 16.59B 501M 2024-09
Perrigo USD 234.8M 36.7M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
Prestige Brands USD 64.13M 3.35M 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Sanofi EUR 2.68B 26M 2024-09
Sanofi EUR 1.24B 1.44B 2024-12
United Therapeutics USD 162.5M 8.4M 2024-12
Zoetis USD 625M 60M 2024-12



Eli Lilly Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Apr 2025.